A list of the costs of four types of drugs will be made from time to time

On December 30, the Sichuan Pharmaceutical Tendering and Procurement Service Center posted a notice on the investigation of the production cost of drugs with abnormal price changes (hereinafter referred to as the "Notice"), which made specific deployment to the investigation of the production cost of price-varying drugs to be carried out in the province from now on."Notice" clearly, the scope of cost investigation will cover the following four types of drugs: First, the State Health Insurance Administration requires the production cost survey of abnormal price changes of drugs;

to make lists of medicines fromIn the investigation of production costs, the Notice puts forward different requirements for domestic and imported drugs. For domestically produced medicines, the survey will include the production costs of the drugs and related production, operations, finance, product flows and prices, while for imported medicines, the focus will be on import costs and related operational, financial, product flows and price data.The notice said the investigation would focus on written investigations, but would take the form of on-the-spot investigations if necessary. For the field investigation of pharmaceutical production enterprises and import enterprises in Sichuan Province, the drug tender and procurement service center of the province shall conduct on-site investigation. For enterprises in other provinces, it is necessary to report to the center on the cost of drug production approved by the local provincial medical security department.It is worth noting that according to the aforementioned four categories of drugs that touch the production cost survey, enterprises will face more stringent investigations into the situation of raising the price of the internet. When a production enterprise requests to raise the price of a drug on the internet, when submitting the application materials for the drug network, it is necessary to submit the cost of production of the drug, which will be used as an important basis for analyzing the rationality of the price increase.On the other hand, for the price increase range or frequency anomalies, regional price differences, the price difference between the same varieties is too large, the circulation link price increase significantly exceeds the reasonable level and insufficient competition in the drug production cost survey, the center will be based on the results of drug price monitoring, from time to time to put forward the need to carry out a production cost survey of the list of drugs, and organize the implementation of the survey, as a basis for analyzing drug prices, take reasonable measures.In addition, the Notice also makes corresponding requirements for the authenticity, accuracy and comprehensiveness of materials such as data, and clearly states that enterprises with problems of non-reporting or false reporting will be treated with false, understreported or unreported relevant information when they review their qualifications for online sales. At the same time, Sichuan will also establish enterprise integrity files based on the investigation of drug production costs, and regularly issue corporate integrity announcements that include information such as the name of the production enterprise, the name of the drug variety, the historical transaction price, and the level of integrity.

low-credit pharmaceutical companies face the most severe punishmentDrug prices are related to the national economy and people's livelihood, is the focus of public concern, the national level frequently out of policy, do more to ensure the stability of drug prices. In the eyes of the industry, Sichuan Province this time to carry out the drug cost survey work is the State Health Insurance Administration "on the current drug price management advice" and other policies specific landing.In the above-mentioned documents, the State Administration of Health Insurance puts forward the opinions of perfecting the mechanism of investigation of drug price cost, and explores the establishment of a mechanism for the punishment of trustworthiness and failure of trust, and sets corresponding incentives or restrictions according to the level of credit. The State Health Insurance Administration recommends that enterprises with high credit rating enjoy preferential treatment under the same conditions, while enterprises with negative credit evaluation will be restricted by various means, such as restricting participation in centralized procurement and including the scope of key supervision of health insurance funds, and that enterprises with serious misreceptions may face disciplinary measures such as suspension of the Internet.Although Sichuan did not specify specific disciplinary provisions in the notice, but from the "Sichuan Province drug online trading production and operation enterprises bad record management measures (trial)" can be seen that Sichuan's treatment of the enterprises involved will not be "soft", the method clearly provides false supporting documents of enterprises, in addition to the cancellation of the enterprise false supporting documents related to the centralized classification of procurement qualifications and results, will also face the most severe penalties involving varieties not included in the centralized classification procurement scope of Sichuan Province for two years.Sichuan has always been a major pharmaceutical province of concern to the industry. In the recently announced second batch of national organizations with the volume of procurement program, in the total number of declared products, according to statistics, Sichuan Province with 1.75 billion declarations ranked fourth, after Guangdong, Beijing and Shandong. Obviously, the "notice" issued will make the province's drug prices more transparent, promote the healthy development of the industry. Industry insiders pointed out that under the baton designed at the top level, drug cost investigation will become the industry's norm, the results of the survey will provide important data support for scientific and reasonable response to abnormal changes in drug prices and guide the formation of drug prices. (Medical Economics)